Protein Sciences Corporation - Product Pipeline Review - 2012

Dec 31, 2012 - Global Markets Direct - 42 pages
Abstract Table of Contents Companies Request Details Related
Table of Contents
Table of Contents
List of Tables
List of Figures
Protein Sciences Corporation Snapshot
Protein Sciences Corporation Overview
Key Information
Key Facts
Protein Sciences Corporation - Research and Development Overview
Key Therapeutic Areas
Protein Sciences Corporation - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Protein Sciences Corporation - Pipeline Products Glance
Protein Sciences Corporation - Late Stage Pipeline
Registration Filed Products/Combination Treatment Modalities
Protein Sciences Corporation Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Protein Sciences Corporation - Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Protein Sciences Corporation - Drug Profiles
ASP-7374
Product Description
Mechanism of Action
R&D Progress
D-3252
Product Description
Mechanism of Action
R&D Progress
PanBlok
Product Description
Mechanism of Action
R&D Progress
Protein Sciences Corporation - Pipeline Products by Route of Administration
Protein Sciences Corporation - Recent Pipeline Updates
Protein Sciences Corporation - Dormant Projects
Protein Sciences Corporation - Locations And Subsidiaries
Head Office
Protein Sciences Corporation, Recent Developments
Protein Sciences Corporation- Press Release
Dec 11, 2012: Astellas And UMN Pharma Complete Administration Of Phase III Clinical Trials Of Seasonal Flu Vaccine ASP7374
Sep 10, 2012: Protein Sciences Announces Presentations Of Clinical Data On FluBlok At ICAAC
Mar 13, 2012: Astellas And UMN Pharma Report Immunogenicity And Favorable Tolerability In Phase II Clinical Trial For H5N1 Influenza Vaccine ASP7373
Oct 05, 2009: UMN Pharma Initiates Phase II Clinical Trial For Avian Influenza A (H5N1) Vaccine Manufactured From Cell-Culture, UMN-0501
Feb 13, 2009: UMN Pharma Presents Favorable Results From Phase I/II Study Of UMN-0501
Financial Deals Landscape
Protein Sciences Corporation, Deals Summary
Protein Sciences Corporation, Pharmaceuticals & Healthcare, Deal Details
Licensing Agreements
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok
Protein Sciences Enters Into Licensing Agreement With UMN Pharma
Debt Offering
Protein Sciences Completes Private Placement Of Convertible Notes For $1 Million
Protein Sciences Completes Private Placement Of Convertible Notes For $6 Million
Asset Transactions
Emergent BioSolutions Acquires FluBlok And Related Technology Assets From Protein Sciences
Acquisition
Vaxine Announced To Acquire Protein Sciences
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Protein Sciences Corporation, Key Information
Protein Sciences Corporation, Key Facts
Protein Sciences Corporation - Pipeline by Indication, 2012
Protein Sciences Corporation - Pipeline by Stage of Development, 2012
Protein Sciences Corporation - Monotherapy Products in Pipeline, 2012
Protein Sciences Corporation - Filed, 2012
Protein Sciences Corporation - Phase II, 2012
Protein Sciences Corporation - Phase I, 2012
Protein Sciences Corporation - Pre-Clinical, 2012
Protein Sciences Corporation - Pipeline By Route of Administration, 2012
Protein Sciences Corporation - Recent Pipeline Updates, 2012
Protein Sciences Corporation - Dormant Developmental Projects,2012
Protein Sciences Corporation, Deals Summary
uniQure Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology
Merck Enters Into Licensing Agreement With Protein Sciences For expresSF+ Insect Cell Technology
Protein Sciences Expands Its Licensing Agreement With UMN Pharma For FluBlok And PanBlok
Protein Sciences Enters Into Licensing Agreement With UMN Pharma
Protein Sciences Completes Private Placement Of Convertible Notes For $1 Million
Protein Sciences Completes Private Placement Of Convertible Notes For $6 Million
Emergent BioSolutions Acquires FluBlok And Related Technology Assets From Protein Sciences
Vaxine Announced To Acquire Protein Sciences

List of Figures
Protein Sciences Corporation - Pipeline by Indication, 2012
Protein Sciences Corporation - Pipeline by Stage of Development, 2012
Protein Sciences Corporation - Monotherapy Products in Pipeline, 2012
Protein Sciences Corporation - Pipeline By Route of Administration, 2012

Order This Report


EASY ORDERING
Once you’ve selected your preferred license option, hit ‘order now’ to complete the checkout process using any major credit card, check or wire/bank transfer.
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.